U.S. Cancer Biopsy Market Foreseen To Increase Exponentially By 2030

U.S. Cancer Biopsy Market Summary

The U.S. cancer biopsy market size was estimated at USD 10.83 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 10.8% from 2025 to 2030. One of the primary factors driving this growth is the rising number of cancer cases across the country. With an aging population, a larger portion of individuals are becoming susceptible to cancer, contributing to the increasing incidence of the disease. Additionally, unhealthy lifestyle choices such as tobacco use, poor dietary habits, and lack of physical activity have further intensified the cancer burden. As more individuals receive cancer diagnoses, the demand for diagnostic procedures like biopsies continues to grow. Biopsies play a crucial role in detecting cancer at early stages, which is essential for initiating timely and effective treatment, thus amplifying the overall demand for cancer biopsy procedures.

Recent advancements in biopsy technology have further contributed to the market’s expansion by making diagnostic procedures more accurate, efficient, and less invasive. For instance, a study published in Nature in September 2023 revealed that a novel spectroscopic liquid biopsy method could identify 99% of stage I cancers with remarkable specificity. This demonstrates the transformative potential of liquid biopsy technologies in improving early cancer detection across various tumor types. Furthermore, techniques such as liquid biopsies, fine-needle aspiration (FNA), and core needle biopsies significantly reduce patient recovery time and the risk of complications, thereby encouraging more widespread use in clinical settings.

Key Market Trends & Insights

• In 2024, the fine-needle aspiration segment led the U.S. cancer biopsy market with a revenue share of 32.2%. This dominance is largely driven by the increased incidence of cancer and a rising preference for minimally invasive diagnostic options. Fine-needle aspiration is particularly favored due to its ability to deliver fast, accurate diagnostic results while minimizing patient discomfort and procedural risk.
• The screening and monitoring segment accounted for the largest revenue share in 2024, fueled by the growing emphasis on preventive healthcare and routine screenings. With increased public awareness about cancer risks and the benefits of early detection, more individuals are opting for regular health check-ups. This trend is fostering demand for biopsy procedures that support timely diagnosis and ongoing monitoring of cancer progression or recurrence.
• In terms of application, the breast cancer segment maintained a significant market share in 2024. Breast cancer remains one of the most commonly diagnosed cancers among women in the U.S., and it requires frequent diagnostic evaluations, including various forms of biopsies, to determine the stage, type, and extent of the disease. These assessments are vital for developing personalized treatment plans and improving patient outcomes.
• The thyroid cancer segment is expected to register the highest CAGR over the forecast period. This accelerated growth is attributed to heightened public awareness regarding thyroid disorders and innovations in biopsy techniques—particularly fine-needle aspiration methods—designed for evaluating thyroid nodules. These minimally invasive procedures enable accurate diagnosis while reducing procedural complexity and patient risk.

Order a free sample PDF of the U.S. Cancer Biopsy Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 10.83 billion
• 2033 Projected Market Size: USD 20.18 billion
• CAGR (2025 - 2030): 10.8%

Key Companies & Market Share Insights

Several key players are actively shaping the U.S. cancer biopsy market landscape. Prominent companies include Becton, Dickinson and Company (BD), IZI Medical Products, Johnson & Johnson Services, Inc., Argon Medical Devices, and SPECTRA MEDICAL DEVICES, LLC. These companies are pursuing strategic initiatives such as mergers, acquisitions, and new product launches to strengthen their market footprint and respond effectively to the evolving healthcare needs of cancer patients in the U.S.

BD offers an extensive range of products that enhance biopsy procedures and cancer diagnostics. These include core biopsy systems like Marquee, Mission, Max-Core, and Magnum, which are engineered to handle diverse tissue types and techniques. The EleVation Breast Biopsy System utilizes Single Insertion Multiple Sample (SIMS) technology to improve sampling efficiency, while the Trek Powered Bone Biopsy System facilitates precise access during bone marrow aspirations.

Johnson & Johnson Services, Inc. contributes to the cancer biopsy field through a variety of innovative diagnostic tools. Notable among them is the CellSearch Liquid Biopsy System, which enables the detection of Circulating Tumor Cells (CTCs) in blood samples—an essential advancement for early-stage cancer diagnosis and ongoing monitoring. Additionally, the company manufactures specialized surgical instruments designed for precise tissue extraction in breast, lung, and gastrointestinal cancers, enhancing both diagnostic accuracy and patient comfort.

Key Players

• BD
• IZI Medical Products
• Johnson & Johnson Services, Inc.
• Argon Medical Devices
• SPECTRA MEDICAL DEVICES, LLC
• Medtronic
• Boston Scientific Corporation
• CONMED Corporation
• INRAD, Inc.
• Thermo Fisher Scientific Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. cancer biopsy market is experiencing strong growth due to rising cancer prevalence, technological advancements, and a shift toward early detection and minimally invasive diagnostics. Techniques like liquid biopsies and fine-needle aspirations are enhancing precision and patient outcomes. Segments such as screening & monitoring and breast cancer diagnostics continue to lead due to high demand for early intervention. Meanwhile, thyroid biopsies show promising growth. Key players are actively innovating and expanding their portfolios to meet evolving needs. As awareness increases and diagnostic technology advances, the cancer biopsy market is expected to play a crucial role in improving cancer care nationwide.